Oncternal Therapeutics In... (ONCT)
NASDAQ: ONCT
· Real-Time Price · USD
0.53
-0.16 (-23.63%)
At close: Dec 02, 2024, 9:00 PM
-23.63% (1D)
| Bid | n/a |
| Market Cap | 1.56M |
| Revenue (ttm) | 1.67M |
| Net Income (ttm) | -34.58M |
| EPS (ttm) | -11.69 |
| PE Ratio (ttm) | -0.04504704875962361 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 644,135 |
| Avg. Volume (20D) | 62,268 |
| Open | 0.70 |
| Previous Close | 0.69 |
| Day's Range | 0.53 - 0.70 |
| 52-Week Range | 0.53 - 10.61 |
| Beta | 1.36 |
About ONCT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ONCT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ONCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
Oncternal Therapeutics shares are trading lowers a...
Unlock content with
Pro Subscription
7 months ago
Octernal Therapeutics shares are trading lower. The company announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer.
9 months ago · seekingalpha.com
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call TranscriptOncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executiv...
